Literature DB >> 10464141

Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis.

A J Czaja1, S Cookson, P K Constantini, M Clare, J A Underhill, P T Donaldson.   

Abstract

BACKGROUND & AIMS: Polymorphisms that control cytokine production can affect immunoregulation. The frequency and consequences of these polymorphisms in type 1 autoimmune hepatitis were determined.
METHODS: DNA samples from 155 patients and 102 ethnically similar normal individuals were assessed by polymerase chain reaction for polymorphisms of 4 different cytokine-producing genes.
RESULTS: Only genotypes associated with the guanine to adenine substitution at position -308 of the tumor necrosis factor gene occurred more commonly in patients than in normal subjects (56% vs. 26%; P < 0.001). Patients with this polymorphism had the HLA DRB1*0301 allele (81% vs. 10%; P < 0.000001) and A1-B8-DRB1*0301 (66% vs. 0%; P < 0.000001) phenotype more frequently and HLA DRB1*04 alleles less often (24% vs. 67%; P < 0.000001). They also entered remission less commonly (56% vs. 78%; P = 0.01), had treatment failure more often (20% vs. 7%; P = 0.03), and developed cirrhosis more frequently (40% vs. 19%; P = 0.05). These latter differences, however, were not statistically significant by adjusted P value.
CONCLUSIONS: A polymorphism of the tumor necrosis factor gene occurs more commonly in patients with type 1 autoimmune hepatitis than in normal subjects; it is associated with a poorer response to corticosteroids. The polymorphism may be inherited as part of the extended A1-B8-DRB1*0301 haplotype and may affect both disease expression and behavior.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10464141     DOI: 10.1016/s0016-5085(99)70458-0

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  35 in total

Review 1.  Genetic bases of autoimmune hepatitis.

Authors:  Albert J Czaja; Derek G Doherty; Peter T Donaldson
Journal:  Dig Dis Sci       Date:  2002-10       Impact factor: 3.199

2.  Relationship between autoimmune hepatitis and HLA-DR4 and DRbeta allelic sequences in the third hypervariable region in Chinese.

Authors:  X Ma; D K Qiu
Journal:  World J Gastroenterol       Date:  2001-10       Impact factor: 5.742

Review 3.  Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2010-01-27       Impact factor: 3.199

Review 4.  Transitioning from Idiopathic to Explainable Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2015-05-22       Impact factor: 3.199

Review 5.  Autoantibody-negative autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2011-12-21       Impact factor: 3.199

6.  Involvement of Th17 and Th1 effector responses in patients with Hepatitis B.

Authors:  Yufu Ye; Xiaojun Xie; Jiwei Yu; Lin Zhou; Haiyang Xie; Guoping Jiang; Xiaobo Yu; Wenjin Zhang; Jian Wu; Shusen Zheng
Journal:  J Clin Immunol       Date:  2010-07       Impact factor: 8.317

7.  Tumor necrosis factor-alpha gene promoter polymorphism in coal workers' pneumoconiosis.

Authors:  Kyoung Ah Kim; Yong-Yeun Cho; Jung Sik Cho; Ki Hwa Yang; Woon Kyu Lee; Kweon-Haeng Lee; Yun Shin Kim; Young Lim
Journal:  Mol Cell Biochem       Date:  2002 May-Jun       Impact factor: 3.396

Review 8.  Acute and acute severe (fulminant) autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-10-23       Impact factor: 3.199

9.  Periportal and sinusoidal liver dendritic cells suppressing T helper type 1-mediated hepatitis.

Authors:  Tomohiro Watanabe; Hiroaki Katsukura; Tsutomu Chiba; Toru Kita; Yoshio Wakatsuki
Journal:  Gut       Date:  2007-10       Impact factor: 23.059

Review 10.  Autoimmune hepatitis.

Authors:  Diego Vergani; Maria Serena Longhi; Dimitrios P Bogdanos; Yun Ma; Giorgina Mieli-Vergani
Journal:  Semin Immunopathol       Date:  2009-06-17       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.